Form 4: Tina Nova, Aurinia Pharmaceuticals Director, Granted Stock Options

Director Tina Nova acquired stock options in Aurinia Pharmaceuticals, exercisable for 63,724 common shares at $8.15, vesting one year from the grant date.

Summary

• Tina Nova, a director of Aurinia Pharmaceuticals Inc., was granted stock options on May 16, 2025.
• The options allow Nova to purchase 63,724 common shares of Aurinia at an exercise price of $8.15 per share.
• The options vest one year from the date of grant and expire on May 16, 2035.
• Following the transaction, Nova directly owns 63,724 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't indicate positive or negative performance, but rather an incentive mechanism.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to increase company value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, director, Aurinia Pharmaceuticals, AUPH, Form 4, beneficial ownership, Tina Nova